Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest Alpha-synuclein Stories

2008-12-11 06:02:00

VIENNA, Austria, December 11 /PRNewswire/ -- AFFiRiS has started pre-clinical development of a Parkinson's vaccine. The vaccine, known as PD01, can be used to target a specific protein that is closely associated with the causes of this degenerative neurological disease. Excellent product candidates from discovery studies have prompted the company to file a patent application and proceed immediately with development. Similarly positive results from external assessments impelled the...

2008-11-04 15:00:05

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has published new research with collaborators at Mayo Clinic in the journal Molecular Neurodegeneration. The new pre-clinical findings demonstrate durable therapeutic silencing of the alpha-synuclein gene when small interfering RNAs (siRNAs), the molecules that mediate RNAi, are administered by direct delivery to the CNS in mice. Alpha-synuclein is believed to play a central role in the...

2007-08-23 03:19:55

By Mrak, Robert E Griffin, W Sue T Abstract Cortical Lewy body disease as a cause of dementia has been recognized for more than 40 years. Only in the past 15 to 20 years, however, has the true frequency of this entity come to be appreciated, primarily because of the advent of sensitive and specific immunohistochemical diagnostic techniques. We now know that there is frequent and extensive overlap, both clinically and pathologically, between Lewy body and Alzheimer diseases. Although some of...

2005-11-16 14:51:38

Researchers at the University of California, San Diego (UCSD) School of Medicine have developed a series of transgenic mouse models of multiple system atrophy, a progressive, fatal neurological disorder. The work is reported in the November 16 issue of the Journal of Neuroscience by Eliezer Masliah, M.D., Professor of Neuroscience and Pathology at UCSD and Cliff Shults, M.D. Professor of Neuroscience at UCSD and Neurologist at the VA San Diego Healthcare System. The mouse models are...

2005-11-03 14:18:53

DALLAS - Nov. 3, 2005 - Researchers at UT Southwestern Medical Center have discovered that a protein associated with causing neurodegenerative conditions may, when appearing in normal amounts, actually protect against neurodegeneration. The findings, appearing in today's issue of the journal Cell, have surprised the researchers, because an excess of the same specific protein - alpha-synuclein - causes Parkinson's disease. "It's the first time that anyone has shown that synuclein has any...

2005-06-21 19:05:00

DALLAS - June 21, 2005 - Researchers at UT Southwestern Medical Center have discovered a mechanism that causes a protein to clump together in brain cells of people with Parkinson's disease, pointing toward a possible treatment for the condition. The protein clumping is part of a "vicious cycle," the researchers said. As the proteins cluster, they inhibit an enzyme that normally breaks them down, leading to the formation of even more masses. "It's a disease involving accumulation of a protein...

2005-06-15 18:08:45

San Diego, Calif. "“ Researchers at the University of California, San Diego (UCSD) School of Medicine working with scientists at Elan Pharmaceuticals, have reported promising results in mice of a vaccine approach to treating Parkinson's and similar diseases. These results appear in the June edition of the journal Neuron. Eliezer Masliah, M.D., Professor of Neurosciences and Pathology at UCSD, and colleagues at UCSD and Elan Pharmaceuticals in San Francisco, vaccinated mice using a a...